FindTrial
Sign In

Evaluating cognitive effects of a three month course of methylphenidate in Parkinson's disease patients with mild cognitive impairment.

Status
Withdrawn
Phases
Phase 2
Study type
Interventional
Source
EU CTIS
Registry ID
CTIS2026-525701-12-00
Enrollment
40
Registered
2026-06-08
Start date
Unknown
Completion date
Unknown
Last updated
2026-06-08

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Parkinson's disease

Brief summary

Electrophysiological markers, Neuropsychological evaluation, UPDRS II and III, PDQ-8 (Parkinson’s disease Questionnaire)

Interventions

DRUGMethylphenidate Viatris 10 mg tabletten
DRUGsaccharine tablets

Sponsors

Universidad Rey Juan Carlos
Lead SponsorOTHER

Eligibility

Sex/Gender
All
Age
18 Years to No maximum

Design outcomes

Primary

MeasureTime frame
Electrophysiological markers, Neuropsychological evaluation, UPDRS II and III, PDQ-8 (Parkinson’s disease Questionnaire)—

Outcome results

None listed

Source: EU CTIS · Data processed: Jun 9, 2026